

Conclusions: Triple knock down of cIAP-1, cIAP-2 and XIAP not only sensitised the androgen independent prostate cancer cells line, PC-3, to TRAIL induced apoptosis but also altered their proliferation rates mediated via a decrease in ID-1 expression. The inability of IAP knock down to alter type 2 triggers of apoptosis demonstrates a maintained mitochondrial stability. IAP knock down may facilitate the bodies natural immune-surveillance mechanisms to counter cancer progression by receptor mediated apoptosis but also therapeutic approaches with TRAIL. Overcoming cancer cell resistance to therapeutic approaches represents an important combined treatment strategy.

308

POSTER

Synergistic anti-tumour activity of oncolytic Reovirus and cisplatin in a B16.F10 mouse melanoma model

L. Heinemann¹, G. Simpson¹, K. Harrington², A. Melcher³, M.C. Coffey⁴, H.S. Pandha⁵. ¹Post Graduate Medical School, Oncology, Guildford, Surrey, United Kingdom; ²Institute of Cancer Research, Targeted Therapy Lab, London, United Kingdom; ³University of Leeds, Oncology, London, United Kingdom; ⁴Oncolytics Biotech, Oncology, Calgary, Canada; ⁵Postgraduate Medical School, Oncology, Guildford, Surrey, United Kingdom

Background: Reovirus type 3 Dearing (RV) has demonstrated oncolytic activity in numerous in vitro systems, in vivo murine models and early clinical trials. In this study, we examine the in vitro and in vivo oncolytic activity of RV against the mouse melanoma cell line B16.F10 in combination with cisplatin (CP), a pseudoalkylating chemotherapeutic which causes DNA cross-linking and is active in a wide range of cancers.

Material and Methods: The effect of RV and CP was assessed in vitro for synergistic tumour kill and mechanism of tumour death. For in vivo evaluation, subcutaneous B16.F10 tumours in C57Bl/6 mice were treated with intratumoural RV and intraperitoneal CP either alone or in combination. Tumour volume was estimated thrice weekly. Tumours and organs were harvested post-treatment for viral retrieval and histology; serum samples were tested for induction of neutralising anti-reovirus antibody (NARA).

Results: A synergistic interaction (combination index value (CIV) of less than one) was observed between RV and CP (CIV: ED50 0.42±0.03; ED75 0.30±0.02; ED90 0.24±0.01). Flow cytometric analysis showed a marked increase in apoptotic cells following combined exposure, compared to single agent exposure. Reduced tumour growth and extended median survival time was observed in mice treated with RV/CP combination therapy compare to single agent treatments. Mean relative tumour volumes ±SD day 12 – Control all reached endpoint, RV alone 8.92±6.94, CP alone 9.87±2.80, RV plus CP 3.86±2.24. Median survival (days) – Control 6, RV 12, CP 8, Combination 17.

Live virus was recovered from the tumours of all RV only treated animals and from the liver and heart of 1/6. In contrast live virus was detected in only 50% of tumours from combination treated mice but in the liver of 4/6 mice. CP did not affect the NARA response to RV.

Conclusions: Taken together, these results indicate that the addition of chemotherapeutic agents can significantly enhance the anti-tumour efficacy of RV therapy and justify formal clinical evaluation.

Her

309

POSTER

Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models

M. Tredler¹, S. Ogbagabriel², R. Moor¹, U. Schulze-Horsel¹, T. Hettmann¹, M. Rothe¹, R. Radinsky², D. Freeman². ¹U3 Pharma, Research, Munich, Germany; ²Amgen Inc, Oncology Research, Thousand Oaks, CA, USA

Background: HER3 is a member of the Human Epidermal Growth Factor Receptor (HER) family and is an important component of HER family driven tumorigenesis. Though HER3 lacks intrinsic kinase activity, it is a scaffold for PI3K/AKT signaling for the HER family via heterodimeric interactions. HER3 signaling may be a resistance mechanism for EGFR and HER2 inhibitors. We report unique in vitro and in vivo activities of U3-1287 (AMG 888), the first fully human Anti-HER3 mAb vs. current HER family inhibitors in NSCLC models. Combinations with EGFR inhibitors are also explored.

Methods: To determine the inhibition of HER3 oncogenic signaling, A549, Calu-3 and H1975 NSCLC cells were treated with up to 10 µg/ml of U3-1287 (AMG 888), C225 (Anti-EGFR), c2C4 (Anti-HER2) or control mAbs 1 hour prior to heregulin-beta (HRG) or vehicle stimulation. Since HER3 is a heterodimerization partner for HER family members, U3-1287 (AMG 888) was combined with EGFR inhibitors in vitro. To determine in vivo efficacy, mice bearing ~200 mm³ A549 NSCLC xenografts were treated 2x/week with anti-HER or control Abs. A549 xenograft tumors were

analyzed for the inhibition of pHER3 by Western blotting. The anti-tumor effects of U3-1287 (AMG 888) with an EGFR inhibitor was tested in the Calu-3 and H1975 NSCLC xenograft models.

Results: Treatment with U3-1287 (AMG 888) resulted in an inhibition of ligand-induced pHER3, basal pHER3 and pAkt in A549, Calu-3 and H1975 NSCLC cell lines, respectively. In NCI-H1975 cells, combining U3-1287 (AMG 888) with the anti-EGFR mAb C225 resulted in greater pHER3 and pAkt inhibition in vitro than with either single agent alone. Administration of U3-1287 (AMG 888) resulted in tumor stasis in the (EGFR TKI resistant) A549 NSCLC xenograft model vs control and other HER mAbs and tumor inhibition in Calu-3 and NCI-H1975 xenografts compared to IgG treated mice (p < 0.05). Combinations with the anti-EGFR mAb C225 resulted in tumor growth inhibition that was greater than either single agent alone in Calu-3 (p < 0.001) and NCI-H1975 (p < 0.001) xenografts.

Conclusions: U3-1287 (AMG 888) inhibits basal and ligand-induced HER3 oncogenic signaling in NSCLC cell lines in vitro and basal pHER3 in vivo. NSCLC xenografts are sensitive to U3-1287 (AMG 888) treatment as single agent or in combination with an anti-EGFR mAb, including an EGFR TKI resistant model. These data provide preclinical evidence for the potential clinical application of U3-1287 (AMG 888) in NSCLC.

310

POSTER

ERBB2/HER2 proteasome-lysosome trafficking and degradation directed by polyubiquitination topology

C. Benz¹, C. Marx¹, J. Held¹, B.W. Gibson¹. ¹Buck Institute for Age Research, Cancer and Developmental Therapeutics Program, Novato, USA

Activity of the overexpressed ERBB2/HER2 receptor tyrosine kinase is related to its cell surface recycling and ability to evade intracellular degradation. Attenuated signaling and receptor degradation may be induced by trafficking that directs internalized receptor to either the ubiquitin-proteasome or lysosome-vacuolar compartments. Ubiquitin covalently links to the epsilon-amine of lysine (K) in target proteins and to one or more of seven K residues in protein-linked ubiquitin, forming branched polyubiquitin chains with different structural topologies capable of directing intracellular trafficking and fate of the tagged protein. In contrast to other receptor tyrosine kinases that are monoubiquitinated and targeted for lysosomal decay, ERBB2 is thought to be ubiquitinated with K-48 branched chains directing its proteasomal degradation. Immunoblotting and confocal imaging have recently shown that when the proteasome is inhibited by PS341 (bortezomib) in ERBB2 overexpressing SKBR3 breast cancer cells, total and surface localized ERBB2 receptor decline within 12–24 h and ERBB2 accumulates in a perinuclear compartment having lysosomal characteristics (e.g. LAMP1/2-positive) and ubiquitin immunoreactivity. Polyubiquitinated ERBB2 appears in concert with gain of Hsp70 and loss of Hsp90 chaperone proteins co-associating with the receptor. Co-treatment of cells with lysosome inhibitors (chloroquine, CA-074-Me) has no effect on ERBB2 receptor trafficking but prevents PS341-induced decline in total ERBB2. To explore the role of K-specific polyubiquitination in targeting ERBB2 for proteasomal and/or lysosomal decay, we developed a multiple reaction monitoring (MRM) mass spectrometry (MS) procedure using a 4000 QTRAP to measure relative levels of endogenous K-48, K-63 and K-29 branched polyubiquitin linked to undegraded ERBB2 receptor immunoprecipitated from SKBR3 cells. MRM-MS analysis showed a rapid rise in K-48 ubiquitinated ERBB2 within 4 h of bortezomib treatment, reaching a 16.5-fold increase by 10 h. In a more delayed fashion, K-63 and K-29 ubiquitinated ERBB2 increased 40-fold and 10-fold, respectively, after 10 h of proteasome inhibition. These changes in receptor trafficking and polyubiquitin chain topology suggest that the accumulation of undegraded K-48 ubiquitinated ERBB2 triggers formation of K-63 and K-29 ubiquitinated ERBB2, redirecting receptor to an alternative degradation pathway within the lysosome.

311

POSTER

In vivo antitumor efficacy of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor

A. Iwahara¹, T. Tamura¹, S. Takagi¹, H. Kamiguchi², T. Yusa¹, Y. Ohta¹. ¹Takeda Pharmaceutical Company Limited, Pharmacology Research Laboratories Li, Tsukuba, Japan; ²Takeda Pharmaceutical Company Limited, Discovery Research Center, Osaka, Japan

Background: HER2 and EGFR are promising targets for effective anticancer drugs. TAK-285, a novel HER2/EGFR dual kinase inhibitor is currently in clinical trials in the United States and Japan. In this study the in vivo efficacy of TAK-285 is demonstrated.

Methods: In vivo antitumor efficacy were examined using xenografts of BT-474 or 4-1ST, which express aberrant levels of HER2. A431, which overexpresses EGFR, was also used. TAK-285 was orally administered twice a day and efficacy was determined by: (growth volume of treated

tumor)/(growth volume of untreated tumor) $\times$ 100 (T/C %). HER2 and EGFR tyrosine phosphorylation in the tumor tissue was detected by Western blot analysis.

Results: TAK-285 demonstrated significant tumor growth inhibition in the BT-474-bearing nude mice in a dose dependent manner with T/C values of 64% at 50 mg/kg, bid, and 29% at 100 mg/kg, bid. Also in 4-1ST-bearing mice TAK-285 showed significant antitumor activity with T/C values of 44% at 50 mg/kg, bid, and 11% at 100 mg/kg, bid.

In vivo antitumor effect of TAK-285 was further studied using the rat xenograft model implanted with 4-1ST. In the dose range about 8 times lower than that of the mice models TAK-285 demonstrated antitumor efficacy (T/C% values of 38% at 6.25 mg/kg and 14% at 12.5 mg/kg) without any body weight reduction. In rats, TAK-285 had a good plasma pharmacokinetic profile and concentrations 5 to 7 times higher in the cancer tissue compared with plasma levels, indicating the reason for the stronger activity. In the rat bearing A431, TAK-285 also showed strong antitumor activity with T/C% values of 48% at 6.25 mg/kg and 13% at 12.5 mg/kg, demonstrating that TAK-285 is efficacious not only for HER2-overexpressing cancers but also for EGFR-overexpressing cancers – an advantage of possessing HER2 and EGFR dual inhibitory activity.

Significant inhibition of HER2 and EGFR phosphorylation by TAK-285 was observed in these tumor xenograft tissues. The reduction of the HER2 phosphorylation level in tumor tissues can be a good biomarker of antitumor efficacy because of the very good correlation between the reduction and antitumor activities. The phosphorylation and activation of Akt and ERK, downstream signaling molecules, were also strongly downregulated after TAK-285 treatment.

Conclusion: TAK-285 showed very good tumor tissue distribution, much higher than that in plasma, and can be efficacious to human cancers with expression not only of HER2 but also of EGFR.

312

POSTER

EZN-3920, an ErbB3-locked nucleic acid-based RNA inhibitor, potentially silences target gene expression in tumor cells grown in vitro and in vivo

B. Liao¹, T. Qu¹, J. Kosek¹, S. Castaneda¹, P. Sapra¹, Y. Zhang¹, R. Bandaru¹, L.M. Greenberger¹, I.D. Horak¹. ¹Enzon Pharmaceuticals, Research, Piscataway, USA

Background: Small molecules and antibodies that target ErbB1 and/or ErbB2 have proven anticancer activity in patients. An addition family member, ErbB3, is unique since it has little or no kinase activity, and therefore is not easily druggable by small molecules. However, inhibition of ErbB3 is likely to have antitumor effects since ErbB3 (1) heterodimerizes with ErbB2 and ErbB1, (2) is a key link to the PI3K pro-survival signaling pathway, and (3) is activated in cells resistant to ErbB1 or ErbB2 therapeutics. In this report, a locked nucleic acid (LNA)-containing antisense oligonucleotide (LNA-ON), designated EZN-3920 and chosen from a panel of ErbB3 LNA-ONs, has been used to inhibit the expression of ErbB3. EZN-3920 is stable in plasma for greater than 72 hours and has very high binding affinity to complementary RNA. The molecule was evaluated in biological models.

Material and Methods: In vitro, the ability of EZN-3920 to knockdown mRNA and inhibit cell growth were evaluated by qRT-PCR and MTS assays, respectively, in several cancer cell lines (derived from prostate, liver, lung, colon and epithelium) after transfection of cells with lipofectamine. In vivo, ErbB3 mRNA silencing in liver and human tumors derived from 15PC-3 (prostate), A549 (lung), and N87 (gastric) cells, which were grown on the flank of nude mice, were evaluated after intravenous administration of EZN-3920 given on multiple regimens. Scrambled LNA-ONs served as controls.

Results: In vitro, EZN-3920 significantly inhibited ErbB3 mRNA expression (IC₅₀ < 4 nM), protein expression, and proliferation (IC₅₀ < 10 nM) in multiple cell lines. These effects were dose-dependent, were not observed with scrambled LNA-ONs, and did not alter levels of an off-target mRNA encoding HIF-1 β . In vivo, up to 90% inhibition of ErbB3 mRNA in the liver was observed after administration of as little as 20 mg/kg EZN-3920 (given qdx5). In addition, EZN-3920 inhibited the expression of ErbB3 mRNA in tumors approximately 50% when given at tolerated doses. The negative control LNA-ONs did not exhibit the target gene silencing effects in liver and tumors.

Conclusions: EZN-3920 potently and specifically inhibits ErbB3 mRNA expression both in vitro and in vivo, particularly in tumors after intravenous injection. Further studies will examine the antitumor efficacy of EZN-3920. EZN-3920 represents a new generation of anticancer agents that may be useful in tumors where ErbB3 is a critical mediator of tumor growth.

313

POSTER

Novel inhibitory mechanisms of TAK-285, a new EGFR/ErbB2 dual inhibitor

S.A. Shell¹, K.J. Pry¹, P. Trusk¹, R.L. Wappel¹, Y. Ohta², W. Klohs³, S.S. Bacus¹. ¹Targeted Molecular Diagnostics, Research and Development, Westmont, USA; ²Takeda Pharmaceutical Company, Pharmacology Research Laboratories, Osaka, Japan; ³Takeda Pharmaceutical Company, T G R D, Deerfield, USA

Background: Activated mutations downstream of EGFR and ErbB2 receptor tyrosine kinases (RTK), such as in KRAS, often render targeted therapy less effective. Furthermore, inactivated mutations in the LKB1 tumor suppressor gene can result in unchecked tumor growth. Therefore, the existence of secondary mutations requires therapeutic regimens beyond inhibiting just the RTK. We show the dual EGFR/ErbB2 inhibitor TAK-285 can kill EGFR-driven tumor cells with activated RAS mutation. Moreover, TAK-285 also activates the AMPK pathway in LKB1-deficient tumor cells. Kinome analysis of TAK-285 showed that the EGFR/ErbB2 inhibitor also binds MEK1/2, downstream enzymes of RAS, with moderate affinity. Thus TAK-285 may demonstrate increased efficacy alone or in combination therapy across a broad spectrum of solid tumors including those harboring activated RAS or inactivated LKB1 mutations.

Materials and Methods: Breast and lung tumor cell lines were treated in triplicate across a range of concentrations (0.01 to 10.0 μ M) with GW2974 (Sigma) or TAK-285 for 72 hours. Changes in cell growth were determined using CellTiter-Glo (Promega) and normalized to DMSO. KinomeScan (Ambit) was performed on TAK-285 at 10.0 μ M across 402 human kinases.

Results: TAK-285 effectively inhibited growth of tumor cells with activated RAS mutation better than GW2974. While both TAK-285 and GW2974 could activate AMPK and inhibit cell growth in LKB1-positive cells, TAK-285 could do the same in LKB1-deficient tumor cells where GW2974 could not. Interestingly, kinome analysis demonstrated TAK-285 binds with moderate affinity to MEK1/2, downstream enzymes of RAS. Moreover, TAK285 showed no significant interaction with members of the AMPK pathway, thus providing insight as to how TAK-285 treatment allows AMPK activation to proceed.

Conclusions: We show that the increased killing of TAK-285 treated tumor cells with activated RAS mutation is likely through TAK-285 to also moderately inhibit MEK1/2, downstream enzymes of RAS. By targeting the oncogenic EGFR pathway upstream by direct EGFR inhibition and downstream by inhibiting enzymes distal to activated RAS, TAK-285 demonstrates better efficacy as a mono-therapy than other drugs that solely target RTKs. Furthermore, by combining MEK inhibitors with TAK-285, synergistic results may be achieved at lower doses. TAK-285 also has the ability to activate the catabolic pathway through AMPK in LKB1-deficient tumor cells adding to its potent killing effects.

314

POSTER

Combined antitumor efficacies of TAK-285, a novel ErbB1/ErbB2 dual kinase inhibitor, with other anticancer drugs

T. Tamura¹, S. Takagi¹, K. Horikoshi¹, T. Yusa¹, M. Koyama¹, H. Tojo¹, Y. Ohta¹. ¹Takeda Pharmaceutical Company Limited, Pharmacology Research Laboratories II, Tsukuba, Japan

Background: The HER tyrosine kinase is a critical target for an effective anticancer drug. Recently we have shown TAK-285, a novel HER2/EGFR dual kinase inhibitor, to be a promising orally available anticancer drug. Here, we report the synergistic antitumor effects with other anticancer drugs. We also address the interaction of TAK-285 with the multidrug resistant (MDR) molecule, which plays a key role in drug-drug interactions.

Methods: The combinational dose-effect relationship on the cell growth inhibition was analyzed using the median-effect method. For the distinct efficacy value, the combination index (CI) was calculated (CI < 1 means synergy, CI = 1 additive, and CI > 1 antagonism). The antitumor effect was also investigated in mice xenograft models. MDR activity was examined by rhodamine efflux via flow cytometry and measurement of ATP consumption.

Results: A clear synergistic antitumor effect (CI < 1) was observed in vitro BT-474 growth assay by the combination of TAK-285 with trastuzumab. Here trastuzumab had no effect against phosphorylation of HER2 while TAK-285 strongly downregulated. The synergistic antitumor effect was confirmed by BT-474 mouse xenograft model. The combination of TAK-285 100 mg/kg, bid, with trastuzumab 10 mg/kg, twice a week, caused strong regression of tumor size. Further, in A431 the synergistic antitumor effect of TAK-285 (CI < 1) was clearly observed in combination with the EGFR-selective inhibitor erlotinib. The precise mechanism of this synergy is not clear, because HER2 expression in A431 is very low. We speculate HER2 signals or its heterodimerization with EGFR still play a key role in A431.